An innovative In-situ method of creating hybrid dendrimer nano-assembly: An efficient next generation dendritic platform for drug delivery

We report an easy in-situ method of creating hybrid dendrimer nano-assembly by mixing G4.0 PAMAM (–NH2) and G3.5 PAMAM (–COONa) dendrimers with a chemotherapeutic drug docetaxel (DTX). Zeta potential, HR-TEM, 1H-NMR proved the formation of nano-assembly. In-vitro dissolution, release studies revealed pH dependent dissolution and sustained drug release. Cellular uptake, cytotoxicity, and flow cytometric analysis in human/mouse glioblastoma cells indicated the effectiveness of hybrid dendrimers. The oral administration of the hybrid dendrimers showed pharmacokinetic equivalence to intravenous injection of commercially available Taxotere®. Hybrid dendrimer concept provides much needed fine-tuning to create multistage next-generation dendritic platform in nanomedicine.Graphical AbstractAn innovative strategy of hybrid dendrimer (In-situ) nano-assembly were developed as a next generation dendritic platform by mixing G4.0 PAMAM (–NH2) and G3.5 PAMAM (–COONa) dendrimers with Docetaxel (DTX) for oral delivery. Zeta Potential, HR-TEM monographs with SAED pattern and 1H-NMR spectra successfully evidenced the formation of supramolecular nano-assembly.Our hybrid dendrimer approach combines the higher solubility, excellent pharmacokinetic performance, safety profile and physicochemical stability of two different dendrimers as a nano-assembly for DTX. We have demonstrated that the oral formulation of hybrid dendrimer approach would be a viable alternative of intravenous Taxotere®...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research